Sandra Boots‐Sprenger

The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone

Remco J. Molenaar, Dagmar Verbaan, Simona Lamba et al. · Neuro-Oncology · 2014 · 208 citations · Full text

MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas

Judith W. M. Jeuken, S.J.B. Cornelissen, Martine Vriezen et al. · Laboratory Investigation · 2007 · 179 citations · Full text

Semiquantitative Detection, Neuro-oncology, Glioma +11

Multiplex Ligation-Dependent Probe Amplification

Judith W. M. Jeuken, S.J.B. Cornelissen, Sandra Boots‐Sprenger et al. · Journal of Molecular Diagnostics · 2006 · 126 citations · Full text

Bioanalysis, Molecular Biology, Nucleic Acid Amplification Test +2

Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution

Sandra Boots‐Sprenger, Angelique Sijben, Jos Rijntjes et al. · Modern Pathology · 2013 · 110 citations · Full text

Neuro-oncology, Somatic Variant, Mgmt Promoter Methylation +13

RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations

Judith W. M. Jeuken, Caroline Van den Broecke, Sabine Gijsen et al. · Acta Neuropathologica · 2007 · 108 citations

Neuro-oncology, Glioma, Medicine +9